癫痫神经调控治疗:已获批疗法现状综述
本文综述三种已获批用于难治性局灶性癫痫的神经调控疗法:迷走神经刺激、丘脑前核深部脑刺激和闭环反应性神经刺激。这些疗法主要为姑息性,仅少数患者实现超过12个月无发作,超过半数患者长期发作频率降低超过50%。植入相关不良事件包括感染和植入部位疼痛,颅内出血是ANT-DBS和反应性神经刺激的常见不良事件。
要点
- 三种神经调控疗法均为姑息性,超过半数患者长期发作频率降低超过50%。
- 仅少数患者实现超过12个月完全无发作。
- 神经调控可考虑用于难治性癫痫患者,但应先评估治愈性手术可能性。
核心结论
- 三种神经调控疗法已获批用于难治性局灶性癫痫,主要为姑息性,超过半数患者长期发作频率降低超过50%,仅少数患者实现超过12个月无发作。
研究设计与样本
- 综述了三种已获批神经调控疗法(VNS、ANT-DBS、闭环反应性神经刺激)在难治性局灶性癫痫中的测试与批准情况。
主要发现
- 仅少数个体通过神经调控疗法实现超过12个月完全无发作。
- 超过半数患者受益于长期发作频率降低超过50%。
- 植入相关不良事件主要包括感染和植入部位疼痛。
- 颅内出血是ANT-DBS和反应性神经刺激的常见不良事件。
- VNS和ANT-DBS可见其他刺激特异性副作用。
临床怎么用
- 神经调控可考虑用于难治性癫痫患者,理想情况下应在仔细评估并排除或判断治愈性手术不合适后使用。
- 目前缺乏预测神经调控治疗反应的生物标志物,也缺乏高级别证据指导何时及对谁优先选择神经调控而非其他抗癫痫治疗。
局限性
- 缺乏预测神经调控治疗反应的生物标志物。
- 缺乏高级别证据帮助决策何时及对谁应优先选择这些疗法而非其他抗癫痫治疗。
- 需要未来研究解决这些知识缺口、批准其他形式的神经调控并开发嵌入机器学习的个性化闭环疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Three neuromodulation therapies have been appropriately tested and approved in refractory focal epilepsies: vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS), and closed-loop responsive neurostimulation of the epileptogenic zone or zones. These therapies are primarily palliative. Only a few individuals have achieved complete freedom from seizures for more than 12 months with these therapies, whereas more than half have benefited from long-term reduction in seizure frequency of more than 50%. Implantation-related adverse events primarily include infection and pain at the implant site. Intracranial haemorrhage is a frequent adverse event for ANT-DBS and responsive neurostimulation. Other stimulation-specific side-effects are observed with VNS and ANT-DBS. Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and for whom these therapies should be preferred over other antiepileptic treatments is scant. Future studies are thus needed to address these shortfalls in knowledge, approve other forms of neuromodulation, and develop personalised closed-loop therapies with embedded machine learning. Until then, neuromodulation could be considered for individuals with intractable seizures, ideally after the possibility of curative surgical treatment has been carefully assessed and ruled out or judged less appropriate.
引用
- Ryvlin P, Rheims S, Hirsch LJ, et al. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021. PMID: 34710360. doi:10.1016/S1474-4422(21)00300-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。